Identifying and treating <i>ROBO1</i>^−ve/<i>DOCK1</i>^+ve prostate cancer: An aggressive cancer subtype prevalent in African American patients

Abstract

We suggest that ROBO1 status forms as predictive biomarker of outcome in high-risk populations such as African-Americans and DOCK1-targeting therapy has a clinical potential for treating metastatic-CaP.